KEVIN C OBOYLE
CIK 1203567 · CFO and Executive VP · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$969.6K
Companies
13
Total Filings
129
Lifetime Open-Market Net
-$14.26M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CARL | Director | 31,031 | $12.31 | $382.0K | $0 | 2 | 2026-06-22 |
| OM | Director | 34,785 | $4.72 | $164.2K | $0 | 3 | 2026-06-05 |
| IRTC | Director | 3,608 | $117.37 | $423.5K | $0 | 2 | 2026-05-29 |
| NEVRO CORP (NVRO) Delisted | Director | 0 | $5.84 | $0 | $301.6K | 10 | 2025-04-03 |
| Sientra, Inc. (SIEN) Delisted | Director | 22,098 | $0.17 | $3.8K | $150.0K | 10 | 2022-06-13 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | Director | 0 | $24.04 | $0 | $3.5K | 19 | 2021-04-22 |
| Wright Medical Group N.V. (WMGI) Delisted | Director | 16,306 | — | — | $0 | 1 | 2019-07-30 |
| Wright Medical Group N.V. (WMGIZ) Delisted | Director | 12,390 | — | — | -$1.82M | 7 | 2019-03-05 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | -$2.40M | 17 | 2017-04-28 |
| Wright Medical Group N.V. (WMGI.Z) Delisted | Director | 17,053 | — | — | $0 | 4 | 2016-10-17 |
| Wright Medical Group N.V. (TRNX) Delisted | Director | 1 | — | — | $0 | 14 | 2015-08-14 |
| Durata Therapeutics, Inc. (DRTX) Delisted | Director | 0 | — | — | $0 | 2 | 2014-11-18 |
| NUVASIVE INC (NUVA) Delisted | CFO and Executive VP | 46,315 | $39.75 | $1.84M | -$10.49M | 37 | 2009-12-17 |
Recent Filings · Page 3 of 13
129 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-05-26 | NEVRO CORP (NVRO) Delisted | Grant (A) | +1,376 | $0 | EDGAR |
| 2020-03-09 | GenMark Diagnostics, Inc. (GNMK) Delisted | Buy (P) | +10,800 | $48.9K | EDGAR |
| 2020-02-27 | GenMark Diagnostics, Inc. (GNMK) Delisted | Grant (A) | +3,973 | $0 | EDGAR |
| 2019-08-19 | GenMark Diagnostics, Inc. (GNMK) Delisted | Mixed | −15,535 | -$119.5K | EDGAR |
| 2019-07-30 | Wright Medical Group N.V. (WMGI) Delisted | Grant (A) | +3,916 | $0 | EDGAR |
| 2019-06-18 | Sientra, Inc. (SIEN) Delisted | Grant (A) | +19,320 | $0 | EDGAR |
| 2019-06-11 | Sientra, Inc. (SIEN) Delisted | Buy (P) | +8,696 | $50.0K | EDGAR |
| 2019-06-07 | NEVRO CORP (NVRO) Delisted | Buy (P) | +1,675 | $100.5K | EDGAR |
| 2019-06-04 | GenMark Diagnostics, Inc. (GNMK) Delisted | Grant (A) | +19,851 | $0 | EDGAR |
| 2019-05-22 | NEVRO CORP (NVRO) Delisted | Grant (A) | +6,049 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.